Its 106 patients required and 10 clinical sites doing the treatments. So you would think they could easily achive this in an accelerated time frame. Dont forget patient follow up was reduced from 52 to 16 weeks.
This stock isnt overpriced for what its trying to achieve. They are going alone in doing this FDA trial with $2m support from the US military. They have enough cash to last them at least up to 2 years.
Tissue therapies is trying to achieve something in the same field as to what avita is doing but they are twice the market value of Avh and are still yet to achieve CE approval and have no revenue.
Wouldnt be surprised if AVH gets an offer from one of the US multinationals currently a giant in the Skin treatment market.
AVH Price at posting:
13.0¢ Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)